HUP0103459A2 - (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval - Google Patents

(2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval

Info

Publication number
HUP0103459A2
HUP0103459A2 HU0103459A HUP0103459A HUP0103459A2 HU P0103459 A2 HUP0103459 A2 HU P0103459A2 HU 0103459 A HU0103459 A HU 0103459A HU P0103459 A HUP0103459 A HU P0103459A HU P0103459 A2 HUP0103459 A2 HU P0103459A2
Authority
HU
Hungary
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
oral dosage
Prior art date
Application number
HU0103459A
Other languages
English (en)
Inventor
Samuel Bruce Balik
Original Assignee
Glaxo Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd. filed Critical Glaxo Group Ltd.
Publication of HUP0103459A2 publication Critical patent/HUP0103459A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány diszkrét orális adagolási formákat szolgáltat - jellemzőentablettákat vagy kapszulákat - amelyek (I) képletű (2S,3S,5R)- 2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinolt vagy annak élettanilagelfogadható sóját vagy szolvátját - vagy az adott só szolvátját -tartalmazzák, kiegészítve hatékony mennyiségű stabilizáló alginsavval.Ezek az adagolási formák alkalmasak a figyelemhiányos, hiperkinetikusbetegség vagy depresszió megelőzésére vagy kezelésére, illetve anikotintartalmú termékekhez - különösképpen a dohányárukhoz - valóhozzászokás kezelésére, így például a dohányzás abbahagyásánakelérésére. Ó
HU0103459A 1998-09-28 1999-09-24 (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval HUP0103459A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Publications (1)

Publication Number Publication Date
HUP0103459A2 true HUP0103459A2 (hu) 2002-01-28

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103459A HUP0103459A2 (hu) 1998-09-28 1999-09-24 (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval

Country Status (17)

Country Link
EP (1) EP1117407A1 (hu)
JP (1) JP2002525328A (hu)
KR (1) KR20010075385A (hu)
CN (1) CN1328459A (hu)
AR (1) AR022673A1 (hu)
AU (1) AU6087399A (hu)
BR (1) BR9914096A (hu)
CA (1) CA2345638A1 (hu)
CZ (1) CZ20011142A3 (hu)
HU (1) HUP0103459A2 (hu)
IL (1) IL142054A0 (hu)
MA (1) MA26693A1 (hu)
NO (1) NO20011555D0 (hu)
PE (1) PE20001087A1 (hu)
PL (1) PL346877A1 (hu)
TR (1) TR200100863T2 (hu)
WO (1) WO2000018406A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
CA2345638A1 (en) 2000-04-06
TR200100863T2 (tr) 2001-07-23
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
CZ20011142A3 (cs) 2001-09-12
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (en) 2000-04-06
NO20011555L (no) 2001-03-27
PE20001087A1 (es) 2000-10-20
EP1117407A1 (en) 2001-07-25
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
NO20011555D0 (no) 2001-03-27
CN1328459A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
AP1760A (en) Platinum derivative pharmaceutical formulations.
BE2011C013I2 (hu)
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
ATE462426T1 (de) Verwendung von saha zur behandlung von mesotheliom
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
HK1076605A1 (en) Formulations
HUP0100900A2 (hu) Gyógyászatilag aktív morfolinolszármazékok, és az ezeket tartalmazó gyógyszerkészítmények
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
SI1664016T1 (sl) Terapevtska sredstva, uporabna za zdravljenje bolečine
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
BG106155A (en) Novel derivatives and analogues of galanthamin
RS20050818A (en) Dosage form containing pantoprazole as active ingredient
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
CY1110659T1 (el) Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος
MXPA06000416A (es) Amidas azaheterociclicas novedosas utiles para tratar el dolor.
HUP0103459A2 (hu) (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
MXPA04004907A (es) Composiciones de acetaminofen.
SE9901572D0 (sv) New compounds